The American Society of Hematology (ASH) has recently promoted efforts to advance the intersection of hematology and aging by sponsoring an annual Scientific Friday Workshop on Hematology and Aging [1]. Hematologic disorders, both malignant and benign, are highly prevalent among older adults [–4]. Despite the disproportionate burden of hematologic disease among older adults [–5], research studying the implications of age across the translational spectrum remains limited older adults understudied [–8]. The lack of pre-clinical aging models, dearth of translational efforts across diseases, and under-enrollment of older adults in clinical trials result in substantial gaps in knowledge. Understanding the interface of human aging and hematologic disorders in a growing population of older adults is warranted. Here we outline the progress to date spearheaded by the ASH community dedicated to hematology and aging.